Upstream Bio Targets Phase 3 Trials for Verekitug in 2027 After Strong Phase 2 Data
Event summary
- Upstream Bio plans to initiate Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027.
- Phase 2 VALIANT trial showed a 56% reduction in asthma exacerbations with verekitug.
- Company has $341.5 million in cash, expected to fund operations through 2027.
- Phase 2 VIBRANT trial data presented at AAAAI reinforced verekitug's potential in CRSwNP.
The big picture
Upstream Bio is advancing its lead candidate verekitug through late-stage development, targeting a high-dose quarterly regimen that could differentiate it in the severe asthma and CRSwNP markets. The company's strong cash position provides runway through 2027, but success will depend on regulatory approval and market acceptance of its differentiated dosing strategy. The biotech is positioning itself as a potential leader in TSLP receptor antagonism, a clinically validated target for inflammatory respiratory diseases.
What we're watching
- Regulatory Alignment
- Whether Upstream Bio can secure FDA alignment on Phase 3 study designs later this year.
- Execution Risk
- The pace at which the company can initiate and complete Phase 3 trials for both indications.
- Market Differentiation
- How verekitug's high-dose quarterly regimen will position it against existing biologic therapies.
Related topics